PDR MEMBER LOGIN:
  • PDR Search

    Required field
  • Advertisement
  • Nitro-Bid
    (nitroglycerin)

    THERAPEUTIC CLASS

    Nitrate vasodilator

    DEA CLASS

    RX

    INDICATIONS

    Prevention of angina pectoris due to coronary artery disease.

    ADULT DOSAGE

    Adults: Initial: 1/2 inch (7.5mg) bid, one applied on rising in the am and one applied 6 hrs later. Titrate: May double the dose, and even double again, in patients tolerating this dose but failing to respond to it. Any regimen of administration should include a daily nitrate-free interval; studies with other nitroglycerin formulations have shown that 10-12 hrs is sufficient.

    ADMINISTRATION

    Topical route. Refer to PI for administration instructions.

    HOW SUPPLIED

    Oint: 2% [1g, foilpac; 30g, 60g, tube]

    WARNINGS/PRECAUTIONS

    Use careful clinical or hemodynamic monitoring to avoid the hazards of hypotension and tachycardia if treating patients with acute myocardial infarction (AMI) or congestive heart failure (CHF). Severe hypotension, particularly with upright posture, may occur with even small doses; caution with volume depletion or hypotension. Nitroglycerin-induced hypotension may be accompanied by paradoxical bradycardia and increased angina pectoris. May aggravate the angina caused by hypertrophic cardiomyopathy. Tolerance and physical dependence may occur.

    ADVERSE REACTIONS

    Headache, lightheadedness.

    DRUG INTERACTIONS

    Amplification of the vasodilatory effects by sildenafil can result in severe hypotension; treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion. Vasodilating effects may be additive with those of other vasodilators (eg, alcohol). Marked symptomatic orthostatic hypotension reported when used with calcium channel blockers; dose adjustments of either drug may be necessary.

    PREGNANCY AND LACTATION

    Category C, caution in nursing.

    MECHANISM OF ACTION

    Nitrate vasodilator; relaxes vascular smooth muscle and consequently dilates peripheral arteries and veins, especially the latter.

    PHARMACOKINETICS

    Distribution: Vd=3L/kg. Metabolism: Inorganic nitrate and 1,2- and 1,3-dinitroglycerols (metabolites). Elimination: T1/2=3 min.

    ASSESSMENT

    Assess for hypersensitivity to organic nitrates, AMI, CHF, volume depletion, hypotension, angina caused by hypertrophic cardiomyopathy, pregnancy/nursing status, and possible drug interactions.

    MONITORING

    Monitor for hypotension, paradoxical bradycardia, increased/aggravated angina pectoris, tolerance, physical dependence, and other adverse reactions. Perform careful clinical or hemodynamic monitoring in patients with AMI or CHF.

    PATIENT COUNSELING

    Inform that daily headaches sometimes accompany treatment and that the headaches are a marker of the activity of the drug; advise to resist the temptation to avoid headaches by altering the schedule of treatment, since loss of headache is likely to be associated with simultaneous loss of antianginal efficacy. Inform that therapy may be associated with lightheadedness on standing, especially just after rising from a recumbent or seated position; counsel that lightheadedness may be more frequent in patients who have consumed alcohol.

    STORAGE

    20-25°C (68-77°F).